Review of Current Issues in Pharmaceutical Excipients - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Review of Current Issues in Pharmaceutical Excipients
Excipients facilitate formulation design and perform a wide range of functions to obtain desired properties for the finished drug product. The article reviews excipient development and functionality of these materials, including their importance in formulation design, potential processing challenges directly related to excipients, and therapeutic benefits.


Pharmaceutical Technology



Potential problems related to excipients
Imprudent selection of excipients and excipient vendors may lead to process-development problems (see sidebar "Potential problems related to excipients").

Excipient and vendor selections can greatly influence development time, performance, quality, and acceptance of final products. Consequently, quality excipient suppliers should:

  • maintain drug master files with FDA for noncompendial items;
  • consistently conform to monograph requirements;
  • manufacture in ISO 9000–certified facilities;
  • pass FDA inspection and auditing by either pharmaceutical companies or International Pharmaceutical Excipient Audit (IPEA, http://www.ipeainc.com/).

Inattention to excipients, excipient suppliers, and regulations may lead to product development failure. Quality-by-design concepts, which have recently been initiated by FDA, emphasize the need for characterizing material properties (e.g., micromeritic, chemical, thermal, rheological, and mechanical properties) and elucidate their vital role in formulation and manufacturing processes (5–8).

New excipients

Currently available excipients are sufficient to support typical formulation development. A significant number of drug entities under development, however, have physicochemical, permeation, and pharmacokinetic properties that are less than ideal. These drugs present formulation challenges and may require either the discovery of new excipients or new applications of existing excipients. Regulatory agencies require new excipients to undergo a series of toxicology tests, which may be costly.

Few new excipients of new chemical entity have been introduced into the market, primarily because of the economic hurdles associated with toxicology testing. Instead, excipient manufacturers have improved excipient performance and have expanded product lines by modifying already approved products (see Table I). Excipients undergoing these approaches may be advantageous in their formulation, manufacture, and marketing. In formulation, these excipients may decrease strain rate sensitivity, increase rework potential, increase dilution potential, decrease lubricant sensitivity, enhance flow properties, enhance the blending process, optimize content uniformity, increase compression ratio, facilitate material handling, require smaller quantities, decrease environmental concerns, and improve stability. These formulation benefits can lead to manufacturing advantages such as enable direct compaction to avoid time-consuming wet granulation, increase production capacity using excipients with enhanced flow and compaction behavior, reduce tablet tooling and machine wear, and eliminate the facility need of solvent recovery. Benefits such as rapid formulation development, smaller tablet size, better quality products, and no solvent residues may be possible by using these excipients with proven functionality.


Table I: Examples of modified excipients.
Many APIs under development have less than ideal physicochemical and absorption properties, resulting in poor bioavailability. Excipient manufacturers have developed enabling excipients such as various solubilizers and absoption enhancers for these hard-to-deliver compounds (e.g., solubilizers hydroxyl propyl β-cyclodextrin; methylated β-cyclodextrin; sulfobutylether β-cyclodextrin; Cremophor RH40, Cremophor EL (BASF), and Solutol HS15 (BASF); Acconon and Captex (Abitec); as well as absorption enhancers Capmul MCM (Abitec); Gelucire 44/14, Gelucire 50/13, Labrasol, and Labrafil (Gattefosse); Imwitor 308 and Imwitor312 (Sasol), vitamin E TPGS (Eastman); and Galacticles (LipoCore)).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here